Managing Parkinson's disease with continuous dopaminergic stimulation.

Area of Science:

• Neurology
• Neuroscience
• Pharmacology

Background:

• Parkinson's disease (PD) pathophysiology involves dopaminergic neuron loss, leading to striatal dopamine deficiency and motor symptoms.
• Current PD treatments, primarily oral levodopa (L-dopa), aim to restore dopamine signaling but often result in motor fluctuations like off periods and dyskinesia with disease progression.
• Refractory motor fluctuations pose significant challenges in managing advanced Parkinson's disease.

Framework:

• Continuous dopaminergic receptor stimulation is proposed as a strategy to overcome the limitations of intermittent oral therapy.
• This approach focuses on maintaining more stable dopaminergic signaling throughout the day.
• Guidelines for individualizing treatment decisions are presented, considering patient-specific factors.

Implementation:

• Continuous levodopa (L-dopa) infusion, particularly duodenal administration, is discussed as an effective method for managing refractory motor fluctuations.
• Subthalamic nucleus deep brain stimulation (STN DBS) is presented as another advanced therapeutic option, involving targeted electrical stimulation.
• Selection criteria for both continuous L-dopa infusion and STN DBS are reviewed, alongside initial data from a Dutch cohort study on duodenal L-dopa/carbidopa.

Implications:

• Continuous dopaminergic stimulation may offer improved motor control and quality of life for Parkinson's disease patients experiencing motor fluctuations.
• Individualized treatment selection between continuous L-dopa infusion and STN DBS is crucial for optimizing patient outcomes.
• Further research and data from cohort studies are essential for refining treatment strategies in advanced Parkinson's disease.